During her presentation, María Jesús Lamas Díaz, director of the AEMPS, defended the need to “support at all levels the development, marketing and permanence of biosimilars”; since, in her opinion, “these are medicines whose quality, effectiveness and safety are comparable to those of reference and essential to modulate the pharmaceutical market.”
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
